A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Required: ARID1A mutation

Required: ARID1A wild-type

Required: BAP1 loss

Allowed: EZH2 hotspot mutation

Must have received: systemic therapy — relapsed/refractory

relapsed following standard therapy or progressed through standard therapy or who have a disease for which no standard effective therapy exists

Must have received: systemic therapy — PTCL: at least 1 prior line; DLBCL: at least 2 prior lines

patients with PTCL must have at least 1 prior line of therapy and patients with DLBCL must have at least 2 prior lines of standard therapy

Must have received: active therapy — mesothelioma: at least 1 prior line

malignant pleural or peritoneal mesothelioma, and have progressed on at least 1 prior line of active therapy

Must have received: androgen-receptor signaling inhibitor — mCRPC: at least 1 prior

mCRPC...have progressed on at least 1 androgen-receptor signaling inhibitor

Must have received: taxane-based chemotherapy (cabazitaxel) — mCRPC: at least 1 prior (cabazitaxel, France only)

at least 1 taxane-based chemotherapy (cabazitaxel, France only)

Must have received: systemic platinum-based chemotherapy — endometrial carcinoma: at least one treatment line in advanced/recurrent disease

at least one treatment line with systemic platinum-based chemotherapy in advanced/ recurrent disease setting

Must have received: anti-PD-1 therapy — endometrial carcinoma: at least one treatment line

anti-programmed cell death protein 1 (PD-1)/ anti-programmed death-ligand 1 (PD-L1) therapy, either in combination or separately, unless these are contraindicated or are not locally accessible

Cannot have received: EZH2 inhibitor

Previous treatment with an EZH2 inhibitor is not allowed